Eptotermin alfa - Ember Therapeutics

Drug Profile

Eptotermin alfa - Ember Therapeutics

Alternative Names: 38A BMP-7 - Ember Therapeutics; Recombinant bone morphogenetic protein-7 - Ember Therapeutics; Recombinant osteogenetic protein-1 - Ember Therapeutics; rhBMP-7 - Ember Therapeutics; rhOP-1 - Ember Therapeutics

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stryker Corporation
  • Developer Ember Therapeutics
  • Class Bone morphogenetic proteins; Calcium regulators; Osteoporosis therapies; Recombinant proteins
  • Mechanism of Action Apoptosis inhibitors; Collagen stimulants; Osteogenesis stimulants; Proteoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Preclinical Nephritis; Renal failure

Most Recent Events

  • 03 Apr 2017 Phase-II development for Osteoarthritis of knee is ongoing in USA (Intra-articular)
  • 06 Jul 2016 Eptotermin alfa licensed to Knight Therapeutics for marketing in Romania and the Caribbean
  • 19 Oct 2015 Eptotermin alfa - Ember Therapeutics is available for licensing as of 19 Oct 2015. http://www.embertx.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top